FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3170021322> ?p ?o ?g. }

• W3170021322 endingPage "e18706" @default.
• W3170021322 startingPage "e18706" @default.
• W3170021322 abstract "e18706 Background: Real-world patients often differ from trial participants in prognostic factors such as age, sex, and cancer substage. New methods combine covariate data from real-world patients (the “target population”) with outcome and covariate data from a trial to estimate treatment effects in the target population that take these differences into account. With some assumptions, these methods can also estimate outcomes under treatment regimens not studied in the trial such as “what if we only gave six cycles of chemotherapy?” or “what if patients all perfectly followed a protocol?” Methods: Data from the MOSAIC trial of 5-fluorouracil (5FU) vs oxaliplatin + 5FU (FOLFOX) were combined with covariate data from a target population of stage III colon cancer patients in the US Oncology Network meeting trial eligibility criteria. We used weighting and G-computation to estimate five-year mortality and treatment-related paresthesia risk in the target population for four regimens: treatment with up to 12 cycles of 5FU, if providers used their discretion on dose reductions and delays (5FU-MD); up to 12 cycles of FOLFOX with similar physician discretion (FOLFOX-MD); up to 6 cycles of FOLFOX, with providers perfectly following a strict and specific protocol of dose reductions and delays (6-cycle FOLFOX-P, “P” for “per protocol”); and up to 12 cycles of FOLFOX, following the same strict protocol (12-cycle FOLFOX-P). Results: Tablepresents five-year all-cause mortality and paresthesia risk under each regimen in the stage III target population estimated from the models built in trial participants. Paresthesia risk increased with cumulative oxaliplatin dose. Estimated 5-year mortality was lowest with 12-cycle FOLFOX-P. Conclusions: In a target population of US Oncology Network patients with stage III colon cancer, strict protocols of 12 cycles of FOLFOX were predicted to improve survival compared to strict 6-cycle FOLFOX regimens or less strict 12-cycle FOLFOX and 5FU regimens at the cost of substantial increases in side effects. While estimates of risk differences in 5-year mortality were imprecise, combining trial and real-world data and then using weights and G-computation allowed estimation of benefits and harms of multiple regimens in a clinically relevant patient population.[Table: see text]" @default.
• W3170021322 created "2021-06-22" @default.
• W3170021322 creator A5024419493 @default.
• W3170021322 creator A5030530617 @default.
• W3170021322 creator A5042519493 @default.
• W3170021322 creator A5043069598 @default.
• W3170021322 creator A5071768751 @default.
• W3170021322 creator A5085949674 @default.
• W3170021322 date "2021-05-20" @default.
• W3170021322 modified "2023-09-23" @default.
• W3170021322 title "Using randomized trial data to estimate effects of complex treatment regimens in real-world patients." @default.
• W3170021322 doi "https://doi.org/10.1200/jco.2021.39.15_suppl.e18706" @default.
• W3170021322 hasPublicationYear "2021" @default.
• W3170021322 type Work @default.
• W3170021322 sameAs 3170021322 @default.
• W3170021322 citedByCount "0" @default.
• W3170021322 crossrefType "journal-article" @default.
• W3170021322 hasAuthorship W3170021322A5024419493 @default.
• W3170021322 hasAuthorship W3170021322A5030530617 @default.
• W3170021322 hasAuthorship W3170021322A5042519493 @default.
• W3170021322 hasAuthorship W3170021322A5043069598 @default.
• W3170021322 hasAuthorship W3170021322A5071768751 @default.
• W3170021322 hasAuthorship W3170021322A5085949674 @default.
• W3170021322 hasConcept C121608353 @default.
• W3170021322 hasConcept C126322002 @default.
• W3170021322 hasConcept C143998085 @default.
• W3170021322 hasConcept C168563851 @default.
• W3170021322 hasConcept C2778260052 @default.
• W3170021322 hasConcept C2780962732 @default.
• W3170021322 hasConcept C2781413609 @default.
• W3170021322 hasConcept C2908647359 @default.
• W3170021322 hasConcept C526805850 @default.
• W3170021322 hasConcept C71924100 @default.
• W3170021322 hasConcept C99454951 @default.
• W3170021322 hasConceptScore W3170021322C121608353 @default.
• W3170021322 hasConceptScore W3170021322C126322002 @default.
• W3170021322 hasConceptScore W3170021322C143998085 @default.
• W3170021322 hasConceptScore W3170021322C168563851 @default.
• W3170021322 hasConceptScore W3170021322C2778260052 @default.
• W3170021322 hasConceptScore W3170021322C2780962732 @default.
• W3170021322 hasConceptScore W3170021322C2781413609 @default.
• W3170021322 hasConceptScore W3170021322C2908647359 @default.
• W3170021322 hasConceptScore W3170021322C526805850 @default.
• W3170021322 hasConceptScore W3170021322C71924100 @default.
• W3170021322 hasConceptScore W3170021322C99454951 @default.
• W3170021322 hasFunder F4320308927 @default.
• W3170021322 hasIssue "15_suppl" @default.
• W3170021322 hasLocation W31700213221 @default.
• W3170021322 hasOpenAccess W3170021322 @default.
• W3170021322 hasPrimaryLocation W31700213221 @default.
• W3170021322 hasRelatedWork W19751876 @default.
• W3170021322 hasRelatedWork W20217714 @default.
• W3170021322 hasRelatedWork W2106863 @default.
• W3170021322 hasRelatedWork W4133181 @default.
• W3170021322 hasRelatedWork W518170 @default.
• W3170021322 hasRelatedWork W5898820 @default.
• W3170021322 hasRelatedWork W6423048 @default.
• W3170021322 hasRelatedWork W7246245 @default.
• W3170021322 hasRelatedWork W7808089 @default.
• W3170021322 hasRelatedWork W8587632 @default.
• W3170021322 hasVolume "39" @default.
• W3170021322 isParatext "false" @default.
• W3170021322 isRetracted "false" @default.
• W3170021322 magId "3170021322" @default.
• W3170021322 workType "article" @default.